Search PubMed⌕ Search

PubMed · 12192544

An update on thyroid surgery.

Abstract

Surgery has been the treatment of choice for many disorders of the thyroid gland, both benign and malignant, for many decades. However, surgery has not been invariable but has continued to change in accordance with research results. In benign cases, surgery has generally evolved to be as organ preserving as possible. In several instances, however, a more radical extent of resection seems justified in order to ensure that the risk of recurrence is as low as possible. For instance, total thyroidectomy may be beneficial in patients with endemic multinodular goitre or young patients with Graves' disease and accompanying cold nodules or high levels of autoantibodies. Several tools, e.g. magnifying glasses, bipolar coagulation forceps and neuromonitoring, are available to identify and preserve the recurrent laryngeal nerve and the parathyroid glands, hence keeping the morbidity at a low level. Most recently, minimally invasive surgery has been successfully used in treating both benign and malignant disorders of the thyroid gland. In the case of malignant disorders, minimally invasive surgery may become an attractive alternative to open surgery if a limited surgical extent is justified, e.g. in patients with micro-PTC (papillary thyroid carcinoma, diameter less than 1 cm). Whether a limited surgical approach is also justified in other cases, e.g. in any patient with intrathyroidal PTC or patients with micro-FTC (follicular thyroid carcinoma), remains to be shown and is the subject of ongoing investigations. One of the most intriguing recent discoveries is the identification of genotype-phenotype correlations in patients with hereditary medullary thyroid carcinoma. In these patients, the timing and extent of surgery may depend not only on the patient's age and serum levels of the tumour marker calcitonin but also on the specific germline RET proto-oncogene mutation. Surgery will certainly continue to play an important role in the treatment of thyroid diseases and may be increasingly based on individual findings instead of general recommendations.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

O Gimm, M Brauckhoff, P N Thanh, C Sekulla, H Dralle. 2002-07-11. An update on thyroid surgery.. https://doi.org/10.1007/s00259-002-0913-3

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Incidence and survival of Swedish patients with differentiated thyroid cancer.

Papillary (PTC) and follicular (FTC) thyroid cancers are rare disorders but are, nevertheless, among the most common cancers in individuals below 40 years of age. From the population-based Swedish Cancer Registry we identified 3,588 individuals with PTC and 1,966 with FTC during 1958-87. Histopathology was determined by examining the original histopathology reports. The relative survival ratio (RSR) was used as the measure of patient survival. Incidence of both PTC and FTC was higher among women, especially for PTC and particularly during the fertile part of female life. Incidence of PTC increased significantly over time, a trend that was not observed for FTC. Five-year relative survival appeared to be higher for patients diagnosed with PTC compared to FTC, although this difference was almost completely explained by the confounding effect of age. Patients with PTC experience lower mortality during the period 7-20 years after diagnosis. Excess mortality was lower among women, although the magnitude of the difference varied with age and histopathology. In contrast to our perceptions based on clinical practice, we observed no difference in excess mortality between patients diagnosed with PTC and FTC during the years immediately after diagnosis (where the majority of deaths occur). Our data suggest that there may exist a subgroup of thyroid tumors with superior prognosis diagnosed in women during the fertile part of female life. Sex hormones may play a role in the etiology of these tumors.

Adenocarcinoma, Follicular↗

Ubiquitous expression of galectin-3 mRNA in benign and malignant thyroid tumors.

We measured the relative expression levels of galectin-3 mRNA to beta-actin mRNA in normal thyroid tissues, thyroid tumor tissues and thyroid-derived fibroblasts. Galectin-3 mRNA was expressed ubiquitously in both benign and malignant thyroid tumors. Although a significant increase in its expression was observed in papillary carcinomas, no significant difference was observed between follicular carcinomas and adenomas. In contrast to the previous optimistic reports using immunohistochemical analysis of the galectin-3 protein expression, these results demonstrate that galectin-3 mRNA may not be a suitable target for molecular-based diagnosis of thyroid carcinomas.

Adenocarcinoma, Follicular↗

[Thyroid carcinomas of the follicular epithelium: tumor markers and oncogenes].

Several genes control cell growth, differentiation and apoptosis. Any alteration in the sequence or expression of these genes can cause an uncontrolled growth of the tissue and produce a tumor. Quantitative and qualitative gene expression studies using genes as tumor markers are essential for the diagnosis and prognosis of the tumor and its behavior. Oncogenes are genes that stimulate cell growth and have an increased expression. On the contrary, tumor suppressor genes are genes that inhibit cell growth and have a decreased expression in tumor cells. To study these tumor markers we apply simple and random molecular biology techniques such as polymerase chain reaction (PCR), reverse transcription and genomic sequencing. In the case of thyroid epithelial neoplasia, tumor markers such as PTEN/MMAC1/TEP1, telomerase, RET/PTC, b-catenine, PAX8/PPAR(1, ciclooxygenase, thyroid stimulating hormonal receptor (TSHR), and thyro-globulin are being investigated. These markers are analyzed for somatic mutations in the genetic sequence, chromosomical rearrangements, alterations in the promoter zone that affect gene expression, regulation and studies of genes at mRNA level. A deeper study of these markers is deemed to help improve the accuracy of tumor diagnosis, behavior and prognosis. Hence, more effective therapeutic options will be adapted to each individual, eventually reducing hospital costs.

Adenocarcinoma, Follicular↗